{
    "name": "lovastatin",
    "comment": "Rx",
    "other_names": [
        "Mevacor",
        "Altoprev"
    ],
    "classes": [
        "Lipid-Lowering Agents",
        "Statins",
        "HMG-CoA Reductase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/mevacor-altoprev-lovastatin-342458",
    "pregnancy": {
        "common": [
            "Owing to HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, fetal harm may occur when administered to pregnant females; discontinue therapy as soon as pregnancy is recognized; limited published data are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage",
            "Advise females of reproductive potential to use effective contraception during treatment",
            "There is no available information on effects of drug on breastfed infant or on milk production",
            "Unknown whether is present in human milk; it has been shown that drugs in this class pass into human milk and atorvastatin is present in rat milk",
            "Not recommended during treatment"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "On July 20, 2021, the ",
                    " request to remove the contraindication against HMG-CoA reductase inhibitors in pregnant females",
                    "Despite the changes, most females found to be pregnant should stop therapy "
                ]
            },
            {
                "type": "FDA MedWatch",
                "description": [
                    "On July 20, 2021, the FDA request to remove the contraindication against HMG-CoA reductase inhibitors in pregnant females",
                    "Breastfeeding is still not recommended if taking statins; drug may still pass through milk and pose a risk breastfed children ",
                    "For patients with lower risk, temporarily stop statin therapy until breastfeeding ends ",
                    "Patients who are at high risk of heart attack or stroke who require statins after delivery should not breastfeed and should use alternatives such as infant formula "
                ]
            },
            {
                "type": "FDA MedWatch",
                "description": [
                    "On July 20, 2021, the FDA request to remove the contraindication against HMG-CoA reductase inhibitors in pregnant females",
                    "Breastfeeding is still not recommended if taking statins; drug may still pass through milk and pose a risk breastfed children ",
                    "For patients with lower risk, temporarily stop statin therapy until breastfeeding ends ",
                    "Patients who are at high risk of heart attack or stroke who require statins after delivery should not breastfeed and should use alternatives such as infant formula "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no available information on effects of drug on breastfed infant or on milk production",
            "Unknown whether is present in human milk; it has been shown that drugs in this class pass into human milk and atorvastatin is present in rat milk",
            "Not recommended during treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to lovastatin or other components",
                "Active liver disease, or unexplained elevated transaminases",
                "Concomitant administration with strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, cobicistat, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, and nefazodone)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Nonserious and reversible cognitive side effects may occur",
                "Avoid coadministration with cyclosporine or gemfibrozil; caution with other fibrates or lipid-lowering doses of niacin (≥1 g/day) because of increased risk for myopathy",
                "Use caution in heavy alcohol use, history of liver disease, or renal failure",
                "Obtain baseline liver enzyme tests before initiating and then periodically thereafter",
                "Increases in HbA1c and fasting serum glucose levels reported",
                "HMG-CoA reductase inhibitor shown to reduce plasma testosterone response to HCG; effects of HMG-CoA reductase inhibitors on male fertility not studied in adequate numbers of male patients",
                "Effects of therapy, if any, on pituitary-gonadal axis in premenopausal women are unknown; patients who develop clinical evidence of endocrine dysfunction should be evaluated appropriately",
                "Use caution if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., spironolactone, cimetidine) that may decrease levels or activity of endogenous steroid hormones",
                "Risk of myopathy increased by coadministration of CYP3A4 inhibitors or other drugs that cause myopathy"
            ],
            "specific": [
                {
                    "type": "Myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria",
                    "description": [
                        "Increased risk can occur at any dose level, but increases in dose-dependent manner",
                        "Predisposing factors for myopathy include advanced age (≥65 years), female gender, renal impairment, and inadequately treated hypothyroidism",
                        "Immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, reported with statin use",
                        "IMNM is characterized by muscle biopsy showing necrotizing myopathy without significant inflammation improvement with immunosuppressive agents, proximal muscle weakness, and elevated serum creatine kinase, which persist despite discontinuation of statin treatment",
                        "Treatment with immunosuppressive agents may be required",
                        "Advice all patients starting therapy or whose dose is being increased, about the risk of myopathy, including rhabdomyolysis",
                        "Patients should report promptly any unexplained muscle pain, tenderness, or weakness particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing therapy; additional neuromuscular and serologic testing may be necessary",
                        "Therapy should be discontinued immediately if myopathy is diagnosed or suspected",
                        "Discontinue therapy if markedly elevated creatine kinase (CK) levels occur or if myopathy diagnosed or suspected",
                        "Therapy should be temporarily withheld in any patient experiencing an acute or serious condition predisposing to development of renal failure secondary to rhabdomyolysis, eg, sepsis; hypotension; dehydration; major surgery; trauma; severe metabolic, endocrine, and electrolyte disorders; or uncontrolled epilepsy",
                        "Consider risk of IMNM carefully prior to initiation of a different statin",
                        "If therapy is initiated with a different statin, monitor for signs and symptoms of IMNM"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for serious reactions such as myopathy including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of lovastatin with itraconazole is contraindicated during and 2 weeks after of itraconazole treatment."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated due to increased risk of rhabdomyolysis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nirmatrelvir",
            "description": {
                "common": "nirmatrelvir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Discontinue lovastatin at least 12 hr before initiating nirmatrelvir/ritonavir."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Discontinue lovastatin at least 12 hr before initiating nirmatrelvir/ritonavir , during the 5 days of treatment, and for 5 days after completing. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increased risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "red yeast rice",
            "description": {
                "common": "lovastatin, red yeast rice.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. May increase creatine kinase levels and increase risk of myopathy or rhabdomyolysis; red yeast rice contains monocolin K (reportedly identical to lovastatin)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "saquinavir",
            "description": {
                "common": "lovastatin will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. This interaction is the net effect of tipranavir being coadministered with ritonavir (boosted therapy); increased risk of myopathy including rhabdomyolysis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "afatinib",
            "description": {
                "common": "lovastatin increases levels of afatinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Reduce afatinib daily dose by 10 mg if not tolerated when coadministered with P-gp inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Do not exceed 40 mg of lovastatin "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aprepitant",
            "description": {
                "common": "aprepitant will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "colchicine",
            "description": {
                "common": "colchicine, lovastatin.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (incl a fatality)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Do not exceed 20 mg/day of lovastatin"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darifenacin",
            "description": {
                "common": "darifenacin will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dasatinib",
            "description": {
                "common": "dasatinib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Do not exceed 20 mg/day of lovastatin"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "lovastatin increases levels of eluxadoline by decreasing metabolism. Avoid or Use Alternate Drug. Decrease eluxadoline dose to 75 mg PO BID if coadministered with OATP1B1 inhibitors. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "erdafitinib will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If coadministration unavoidable, separate administration by at least 6 hr before or after administration of P-gp substrates with narrow therapeutic index."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "everolimus",
            "description": {
                "common": "lovastatin will increase the level or effect of everolimus by  P-glycoprotein (MDR1) efflux transporter. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fenofibrate",
            "description": {
                "common": "fenofibrate, lovastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs. Do not exceed 20 mg/day of lovastatin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fenofibrate micronized",
            "description": {
                "common": "fenofibrate micronized, lovastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs. Do not exceed 20 mg/day of lovastatin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fenofibric acid",
            "description": {
                "common": "fenofibric acid, lovastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs. Do not exceed 20 mg/day of lovastatin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosaprepitant",
            "description": {
                "common": "fosaprepitant will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemfibrozil",
            "description": {
                "common": "gemfibrozil, lovastatin.\nEither increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Gemfibrozil may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs. Do not exceed 20 mg/day of lovastatin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "glecaprevir/pibrentasvir increases levels of lovastatin by Other (see comment). Avoid or Use Alternate Drug. \nComment: Increased statin concentrations resulting from OATP1B1 inhibition may increase risk of myopathy, including rhabdomyolysis. Coadministration of glecaprevir/pibrentasvir with lovastatin is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid large quantities of grapefruit juice (ie, >1 quart daily)"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "griseofulvin",
            "description": {
                "common": "griseofulvin will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lapatinib",
            "description": {
                "common": "lapatinib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan increases levels of lovastatin by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of lovastatin by  Other (see comment). Avoid or Use Alternate Drug. Leniolisib, an OATP1B1 and OATP1B3 inhibitor, may increase systemic exposure of these substrates "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lomitapide",
            "description": {
                "common": "lomitapide increases levels of lovastatin by decreasing metabolism. Avoid or Use Alternate Drug. Reduce lovastatin dose by 50% when initiating lomitapide dosing."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "lumefantrine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "marijuana",
            "description": {
                "common": "marijuana will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mesterolone",
            "description": {
                "common": "mesterolone increases toxicity of lovastatin by decreasing metabolism. Avoid or Use Alternate Drug. Risk of rhabdomyolysis (case reports of combination of danazol and >20 mg/day lovastatin)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metronidazole",
            "description": {
                "common": "metronidazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "miconazole vaginal",
            "description": {
                "common": "miconazole vaginal will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "niacin",
            "description": {
                "common": "niacin, lovastatin.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (>1 g/day niacin). Do not exceed 20 mg/day of lovastatin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nilotinib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pomalidomide",
            "description": {
                "common": "lovastatin increases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinupristin/dalfopristin",
            "description": {
                "common": "quinupristin/dalfopristin will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "riociguat",
            "description": {
                "common": "lovastatin will increase the level or effect of riociguat by  decreasing metabolism. Avoid or Use Alternate Drug. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rufinamide",
            "description": {
                "common": "rufinamide will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tepotinib",
            "description": {
                "common": "tepotinib will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If concomitant use unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trofinetide",
            "description": {
                "common": "trofinetide will increase the level or effect of lovastatin by  Other (see comment). Avoid or Use Alternate Drug. Trofinetide (an OATP131 and OATP13B inhibitor) may increase plasma levels of OATP131 or OATP13B substrates. Avoid coadministration with sensitive substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Do not exceed 20 mg of lovastatin "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voxelotor",
            "description": {
                "common": "voxelotor will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zafirlukast",
            "description": {
                "common": "zafirlukast will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of lovastatin by  increasing elimination. Use Caution/Monitor. Apalutamide induces UGT and may decrease systemic exposure of drugs that are UGT substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "lovastatin will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "atorvastatin will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "lovastatin will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "axitinib",
            "description": {
                "common": "lovastatin increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azithromycin",
            "description": {
                "common": "azithromycin will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bazedoxifene/conjugated estrogens",
            "description": {
                "common": "lovastatin will increase the level or effect of bazedoxifene/conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "berotralstat",
            "description": {
                "common": "berotralstat will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor or titrate P-gp substrate dose if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosutinib",
            "description": {
                "common": "bosutinib increases levels of lovastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "lovastatin increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of lovastatin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholic acid",
            "description": {
                "common": "lovastatin increases toxicity of cholic acid by decreasing elimination. Modify Therapy/Monitor Closely. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). May exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clotrimazole",
            "description": {
                "common": "clotrimazole will decrease the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "lovastatin will increase the level or effect of conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens, vaginal",
            "description": {
                "common": "lovastatin will increase the level or effect of conjugated estrogens, vaginal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crofelemer",
            "description": {
                "common": "crofelemer increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daptomycin",
            "description": {
                "common": "lovastatin, daptomycin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "deferasirox will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "lovastatin will increase the level or effect of deflazacort by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "lovastatin will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "docetaxel",
            "description": {
                "common": "lovastatin will increase the level or effect of docetaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for signs and symptoms of myopathy in patients receiving dronedarone concurrently with lovastatin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duvelisib",
            "description": {
                "common": "duvelisib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elbasvir/grazoprevir",
            "description": {
                "common": "elbasvir/grazoprevir increases levels of lovastatin by unknown mechanism. Modify Therapy/Monitor Closely. If coadministered, use lowest necessary lovastatin dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat increases levels of lovastatin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib, lovastatin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Dose adjustment of some statins may be needed if a clinically significant change in lipids is noted. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol",
            "description": {
                "common": "lovastatin will increase the level or effect of estradiol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "lovastatin will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "lovastatin will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostamatinib",
            "description": {
                "common": "fostamatinib will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Concomitant use of fostamatinib may increase concentrations of P-gp substrates. Monitor for toxicities of the P-gp substrate drug that may require dosage reduction when given concurrently with fostamatinib."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir will increase the level or effect of lovastatin by  Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits OATP1B1/3 transporter. If possible, avoid coadministration or modify dose of OATP1B1/3 substrates coadministered with fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "glecaprevir/pibrentasvir will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "lovastatin will increase the level or effect of hydrocortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "lovastatin will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "lovastatin will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "ivacaftor increases levels of lovastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp; may significantly increase systemic exposure to sensitive P-gp substrates with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivermectin",
            "description": {
                "common": "lovastatin will increase the level or effect of ivermectin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lanthanum carbonate",
            "description": {
                "common": "lanthanum carbonate decreases levels of lovastatin by cation binding in GI tract. Use Caution/Monitor. Administer statin at least 2 hr before or 2 hr after lanthanum. Monitor serum concentrations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lapatinib",
            "description": {
                "common": "lapatinib will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lovastatin will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Initiate lovastatin with the lowest starting dose and titrate carefully while monitoring for safety (eg, myopathy)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "lovastatin increases levels of letermovir by increasing metabolism. Use Caution/Monitor. Coadminstration of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase letermovir plasma concentrations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "lovastatin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loperamide",
            "description": {
                "common": "lovastatin will increase the level or effect of loperamide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "lovastatin will increase the level or effect of maraviroc by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "lovastatin will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mipomersen",
            "description": {
                "common": "mipomersen, lovastatin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Both drugs have potential to increase hepatic enzymes; monitor LFTs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane decreases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine will decrease the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "lovastatin will increase the level or effect of nilotinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "lovastatin will increase the level or effect of paclitaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "lovastatin will increase the level or effect of paclitaxel protein bound by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "lovastatin will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponatinib",
            "description": {
                "common": "ponatinib increases levels of lovastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quercetin",
            "description": {
                "common": "quercetin will decrease the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranolazine",
            "description": {
                "common": "ranolazine will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "lovastatin will increase the level or effect of sacubitril/valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "sarecycline will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "silodosin",
            "description": {
                "common": "lovastatin will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "simvastatin",
            "description": {
                "common": "simvastatin will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "lovastatin will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, lovastatin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "lovastatin will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "ticagrelor increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid lovastatin doses greater than 40 mg."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "lovastatin will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "lovastatin will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone will decrease the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "lovastatin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "vemurafenib increases levels of lovastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid concomitant use of verapamil and lovastatin if possible. If used together, use lower doses of lovastatin and monitor for lovastatin toxicity (myositis, rhabdomyolysis)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vinblastine",
            "description": {
                "common": "lovastatin will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vincristine",
            "description": {
                "common": "lovastatin will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vincristine liposomal",
            "description": {
                "common": "lovastatin will increase the level or effect of vincristine liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "lovastatin increases effects of warfarin by anticoagulation. Use Caution/Monitor. Dosage adjustment of anticoagulant based in INR and clinical response may be necessary."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alvimopan",
            "description": {
                "common": "lovastatin will increase the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "coenzyme Q10",
            "description": {
                "common": "lovastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colestipol",
            "description": {
                "common": "colestipol decreases levels of lovastatin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "exenatide injectable solution",
            "description": {
                "common": "exenatide injectable solution decreases levels of lovastatin by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "exenatide injectable suspension",
            "description": {
                "common": "exenatide injectable suspension decreases levels of lovastatin by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fexofenadine",
            "description": {
                "common": "lovastatin will increase the level or effect of fexofenadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isradipine",
            "description": {
                "common": "isradipine decreases levels of lovastatin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "liraglutide",
            "description": {
                "common": "liraglutide decreases levels of lovastatin by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "loratadine",
            "description": {
                "common": "lovastatin will increase the level or effect of loratadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "orlistat",
            "description": {
                "common": "orlistat increases effects of lovastatin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "lovastatin will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "lovastatin will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone increases levels of lovastatin by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin will increase the level or effect of lovastatin by  Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "CPK elevation",
            "percent": "11"
        },
        {
            "name": "Flatulence",
            "percent": "4-5"
        },
        {
            "name": "Abdominal pain",
            "percent": "2-3"
        },
        {
            "name": "Constipation",
            "percent": "2-3"
        },
        {
            "name": "Diarrhea",
            "percent": "2-3"
        },
        {
            "name": "Myalgia",
            "percent": "2-3"
        },
        {
            "name": "Nausea",
            "percent": "2-3"
        },
        {
            "name": "Dyspepsia",
            "percent": "1-2"
        },
        {
            "name": "Weakness",
            "percent": "1-2"
        },
        {
            "name": "Blurred vision",
            "percent": "0.8-1"
        },
        {
            "name": "Rash",
            "percent": "0.8-1"
        },
        {
            "name": "Muscle cramps",
            "percent": "0.6-1"
        },
        {
            "name": "Dizziness",
            "percent": "0.5-1"
        },
        {
            "name": "Dermatomyositis",
            "percent": null
        },
        {
            "name": "Increased LFTs",
            "percent": null
        },
        {
            "name": "Hepatotoxicity",
            "percent": null
        },
        {
            "name": "Myopathy",
            "percent": null
        },
        {
            "name": "Rhabdomyolysis",
            "percent": null
        },
        {
            "name": "Interstitial lung disease",
            "percent": null
        }
    ]
}